Deborah J Marsh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/430523/publications.pdf

Version: 2024-02-01

90 papers 4,026 citations

172457 29 h-index 62 g-index

90 all docs

90 docs citations

90 times ranked 5501 citing authors

#	Article	IF	CITATIONS
1	Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 827-836.	3.6	560
2	A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 2005, 1, e8.	3.5	394
3	Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults. American Journal of Human Genetics, 2003, 73, 1191-1198.	6.2	213
4	Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. American Journal of Surgical Pathology, 2006, 30, 1140-1149.	3.7	213
5	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 2012, 12, 627.	2.6	163
6	Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Scientific Reports, 2016, 6, 26191.	3.3	162
7	Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs. PLoS ONE, 2016, 11, e0153200.	2.5	160
8	Comparative Genomic Hybridization Analysis of Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3467-3474.	3.6	125
9	Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 434-441.	3.6	120
10	Rapamycin treatment for a child with germline PTEN mutation. Nature Clinical Practice Oncology, 2008, 5, 357-361.	4.3	114
11	Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene, 2003, 22, 1358-1364.	5.9	108
12	Histone H2B monoubiquitination: roles to play in human malignancy. Endocrine-Related Cancer, 2015, 22, T19-T33.	3.1	108
13	The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocrine-Related Cancer, 2010, 17, 929-940.	3.1	98
14	Gene Expression of Parathyroid Tumors. Cancer Research, 2004, 64, 7405-7411.	0.9	96
15	Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Research, 2014, 16, R63.	5.0	90
16	The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination. Human Molecular Genetics, 2012, 21, 559-568.	2.9	85
17	Genetic insights into familial cancers – update and recent discoveries. Cancer Letters, 2002, 181, 125-164.	7.2	75
18	Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. American Journal of Surgical Pathology, 2019, 43, 35-46.	3.7	74

#	Article	IF	Citations
19	Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene, 2005, 24, 6241-6248.	5.9	65
20	Genome-Wide Copy Number Imbalances Identified in Familial and Sporadic Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1866-1872.	3.6	54
21	A Case Report in Favor of a Multistep Adrenocortical Tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 998-1001.	3.6	54
22	Gonadotropin signalling in epithelial ovarian cancer. Cancer Letters, 2012, 324, 152-159.	7.2	50
23	Histones and Their Modifications in Ovarian Cancer ââ,¬â€œ Drivers of Disease and Therapeutic Targets. Frontiers in Oncology, 2014, 4, 144.	2.8	46
24	Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Letters, 2007, 581, 5070-5074.	2.8	44
25	Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase Cl´. Endocrine-Related Cancer, 2010, 17, 335-349.	3.1	40
26	Host-Guest Complexes of Carboxylated Pillar[n]arenes With Drugs. Journal of Pharmaceutical Sciences, 2016, 105, 3615-3625.	3.3	40
27	CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 2010, 17, 273-282.	3.1	37
28	Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism. American Journal of Pathology, 2002, 161, 1299-1306.	3.8	36
29	Writing Histone Monoubiquitination in Human Malignancyâ€"The Role of RING Finger E3 Ubiquitin Ligases. Genes, 2019, 10, 67.	2.4	35
30	Rapid Mutation Scanning of Genes Associated with Familial Cancer Syndromes Using Denaturing High-Performance Liquid Chromatography. Neoplasia, 2001, 3, 236-244.	5.3	31
31	Genetic Testing in Pheochromocytoma- and Paraganglioma-Associated Syndromes. Annals of the New York Academy of Sciences, 2006, 1073, 104-111.	3.8	28
32	Tissue biomarkers of breast cancer and their association with conventional pathologic features. British Journal of Cancer, 2013, 108, 351-360.	6.4	27
33	Mutational Analysis and Genotype-Phenotype Correlation of the PHEX Gene in X-Linked Hypophosphatemic Rickets. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3889-3899.	3.6	27
34	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. Human Molecular Genetics, 2016, 25, ddw362.	2.9	26
35	Histone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and Cancer. Cancers, 2020, 12, 3462.	3.7	26
36	Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer. Gynecologic Oncology, 2018, 148, 181-188.	1.4	25

#	Article	IF	CITATIONS
37	Protein Chip Discovery of Secreted Proteins Regulated by the Phosphatidylinositol 3-Kinase Pathway in Ovarian Cancer Cell Lines. Cancer Research, 2006, 66, 1376-1383.	0.9	24
38	Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosomes and Cancer, 2015, 54, 1-19.	2.8	23
39	Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. Frontiers in Bioengineering and Biotechnology, 2022, 10, 836984.	4.1	22
40	K40E: a novel succinate dehydrogenase (SDH)B mutation causing familial phaeochromocytoma and paraganglioma. Clinical Endocrinology, 2004, 61, 510-514.	2.4	21
41	Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opinion on Medical Diagnostics, 2007, 1, 377-392.	1.6	21
42	Denaturing High Performance Liquid Chromatography Detection of SDHB, SDHD, and VHL Germline Mutations in Pheochromocytoma. Journal of Surgical Research, 2009, 157, 55-62.	1.6	20
43	A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer. Cancer Letters, 2015, 368, 64-70.	7.2	19
44	Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells. Journal of Biological Chemistry, 2011, 286, 29540-29547.	3.4	18
45	Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway. Gene, 2002, 298, 9-19.	2.2	17
46	A molecular diagnosis of hyperparathyroidismâ€"Jaw tumor syndrome in an adolescent with recurrent kidney stones. Journal of Pediatrics, 2004, 145, 567.	1.8	16
47	Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. Journal of Molecular Diagnostics, 2006, 8, 559-566.	2.8	16
48	Multiple Endocrine Neoplasia: Types 1 and 2. Advances in Oto-Rhino-Laryngology, 2011, 70, 84-90.	1.6	14
49	Hypercalcaemia due to parathyroid carcinoma presenting in the third trimester of pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 204-207.	1.0	13
50	Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells. Cancer Letters, 2012, 317, 41-48.	7.2	11
51	An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles. Journal of Materials Chemistry B, 2021, 9, 9123-9135.	5.8	11
52	The effect of disease-associated HRPT2 mutations on splicing. Journal of Endocrinology, 2009, 201, 387-396.	2.6	10
53	Mutant AKT1 in Proteus Syndrome. New England Journal of Medicine, 2011, 365, 2141-2142.	27.0	10
54	Factors that May Influence the Willingness of Cancer Patients to Consent for Biobanking. Biopreservation and Biobanking, 2014, 12, 409-414.	1.0	10

#	Article	IF	CITATIONS
55	Ubiquitin chromatin remodelling after DNA damage is associated with the expression of key cancer genes and pathways. Cellular and Molecular Life Sciences, 2021, 78, 1011-1027.	5.4	10
56	The Use of Denaturing High Performance Liquid Chromatography (DHPLC) for Mutation Scanning of Hereditary Cancer Genes. Methods in Molecular Biology, 2010, 653, 133-145.	0.9	10
57	Genetics of pheochromocytoma and paraganglioma. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 79-86.	0.6	9
58	Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency. Scientific Data, 2017, 4, 170120.	5. 3	9
59	Diagnosis of Proteus syndrome was correct. American Journal of Medical Genetics Part A, 2004, 130A, 214-215.	2.4	8
60	PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 8506.	4.1	8
61	Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma: the role of parafibromin in increasing diagnostic accuracy. Internal Medicine Journal, 2011, 41, 695-699.	0.8	6
62	Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling. Molecular and Cellular Endocrinology, 2021, 533, 111338.	3.2	6
63	The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics, 2022, 14, 837.	4.5	6
64	Toward Systems Pathology for PTEN Diagnostics. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037127.	6.2	4
65	Match that PhD. Nature, 2015, 523, 247-247.	27.8	2
66	Networks regulating ubiquitin and ubiquitin-like proteins promise new therapeutic targets. Endocrine-Related Cancer, 2015, 22, E1-E3.	3.1	1
67	Studying the Oncosuppressive Functions of PTENP1 as a ceRNA. Methods in Molecular Biology, 2021, 2324, 165-185.	0.9	1
68	Abstract A29: Loss of histone H2B monoubiquitination in ovarian cancer $\hat{a} \in \text{``}$ new therapeutic targeting opportunities based on chromatin relaxation. , 2013, , .		1
69	HRPT2 and parathyroid cancer. Lancet Oncology, The, 2004, 5, 78.	10.7	0
70	Lessons learnt from outstanding mid-career women in endocrine cancer research. Endocrine-Related Cancer, 2016, 23, E5-E7.	3.1	0
71	Abstract 1062: Inhibition of ovarian and endometrial cancer cell proliferation by an anti-ROR1 monoclonal antibody., 2021,,.		0
72	Von Hippel–Lindau Disease. , 2004, , 1329-1333.		0

#	Article	IF	CITATIONS
73	Cowden Syndrome. , 2004, , 301-304.		O
74	Abstract 4962: Assessing serum miRNA as putative biomarkers for serous epithelial ovarian cancer. , $2011, \ldots$		0
75	Abstract 2167: The tumor suppressor CDC73/parafibromin is required for the maintenance of histone 2B monoubiquitination bothin vitroandin vivo. , 2012, , .		0
76	Abstract 3150: miR-100 in ovarian cancer cell lines. , 2012, , .		0
77	Abstract 330: Utilization of Sleeping Beauty mutagenesis for the identification of potential driver genes of ovarian cancer, 2013, , .		0
78	Abstract A10: A mutagenesis screen identifies tumor suppressors and kinases as potential driver genes of ovarian cancer. , $2013, \dots$		0
79	Cowden Syndrome. , 2014, , 1-6.		0
80	Abstract 1047: A role for the free beta subunit of human chorionic gonadotropin in sensitivity of epithelial ovarian cancer cells to platinum-based chemotherapeutics. , 2015 , , .		0
81	Histone H2B. , 2016, , 1-5.		0
82	CDC73., 2016, , 1-5.		0
83	Abstract B05: Assessment of TP53 mutation status in primary high-grade serous ovarian cancer and cell line models: Comparison between immunohistochemistry and next-generation sequencing , 2016, , .		0
84	Cowden Syndrome. , 2016, , 1218-1222.		0
85	Histone H2B. , 2018, , 2384-2388.		0
86	CDC73., 2018,, 991-995.		0
87	Abstract 3538: Targeting the E3 ubiquitin ligase RNF20 in ovarian cancer. , 2018, , .		0
88	Abstract A06: Cisplatin-induced DNA damage modifies the chromatin landscape of histone H2B monoubiquitination in a p53-dependent manner. , 2018, , .		0
89	The role of the free \hat{I}^2 -subunit of human chorionic gonadotropin in human malignancy. , 2020, , 269-281.		0
90	Cowden Syndrome. , 2008, , 759-762.		0